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aTATE-OF-THE-ART PAPER1209Models for the Assessment of Cardiovascular Riskarie Therese Cooney, Alexandra L. Dudina, Ian M. Graham
n this review, Cooney and colleagues define the term ”risk factor” and outline the concept of
nd rationale for total cardiovascular risk estimation. The characteristics of a clinically-useful
isk estimation system include discrimination, reclassification, and usability, and all of these
erms are defined and described with examples. The multitude of current risk estimation
ystems, such as Framingham, SCORE (Systematic COronary Risk Evaluation), and
RISK, are described and compared. The limitations of these systems are described,
articularly the challenge of risk estimation in the young and the old.ARDIOVASCULAR GENOMIC MEDICINE1228Risk Stratifying PAD With Biomarkers and Genetic AnalysesCirculating 
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cDermott and Lloyd-Jones review the role of inflammation and genetic mutations in the
rogression of peripheral arterial disease (PAD). Patients with PAD have higher levels of
irculating inflammatory biomarkers, particularly C-reactive protein, D-dimer, and
nterleukin-6. Some studies have linked levels of these biomarkers to worse outcomes,
ncluding more functional impairment, greater declines in the ankle brachial index, graft
estenosis, and higher rates of cardiovascular mortality. While available data suggest a modest
egree of heritability for PAD, the culprit gene or genes have not been consistently identified,
nd thus there is currently insufficient data to recommend genetic testing for PAD.(continued on page A-18)
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EORONARY DISEASE RISK1238Genetic Variation in Paraoxonase Gene Linked to Risk of Cardiac Deathakub J. Regieli, J. Wouter Jukema, Pieter A. Doevendans, Aeilko H. Zwinderman, John J. Kastelein,
iederick E. Grobbee, Yolanda van der Graaf
araoxonase (PON)-1 is a plasma protein residing on high-density lipoprotein (HDL) that
ppears to influence the antioxidant properties of HDL including the rate of oxidization of
ow-density lipoprotein. Regieli and colleagues investigated the effects of variation in the
ON-1 gene on the long-term clinical outcome of patients with coronary artery disease
CAD). A marked allele-dose effect was visible from the survival curves. For instance, the
0-year absolute risk of death due to ischemic heart disease was 4.6% in L55 homozygote
atients, whereas it was 7.1% in heterozygote patients and 10.9% in 55M homozygote
atients. PON-1 gene variants influence the risk of fatal complications from CAD and
uggest that this enzyme might be a target for modification.ditorial Comment: H. Robert Superko, p. 1246ORONARY DISEASE RISK1249Measuring the Cardiovascular Benefit of Banning Public Smokingavid G. Meyers, John S. Neuberger, Jianghua He
econdhand smoke (SHS) acutely increases the risk of acute myocardial infarction (AMI).
everal localities have recently enacted bans on smoking in public places and workplaces, but
he risk reduction with these bans is not widely known. Meyers and colleagues performed a
ystematic literature review and meta-analysis, including studies of both small cities and
ountry-wide interventions, to estimate the effect of workplace and public smoking bans.
verall, acute myocardial infarction (AMI) risk decreased by 17% comparing pre- and post-
an AMI rates. The risk of AMI continued to decrease by 26% annually after ban implemen-
ation. These results confirm that public smoking bans can reduce the incidence of AMI.
ditorial Comment: Steven A. Schroeder, p. 1256(continued on page A-22)
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TOST-EFFECTIVENESS1258Downstream Cardiac Testing After CAC Screeningeslee J. Shaw, James K. Min, Matthew Budoff, Heidi Gransar, Alan Rozanski, Sean W. Hayes,
ohn D. Friedman, Romalisa Miranda, Nathan D. Wong, Daniel S. Berman
espite evidence that coronary artery calcium (CAC) screening can more accurately risk
tratify individuals, there remains concern that testing will beget more testing and will result
n early and lifelong higher patterns of resource consumption with little clinical benefit. Shaw
nd colleagues followed cardiac resource utilization over 4 years in individuals who underwent
AC screening. Stress imaging was more often performed in those with CAC scores 400.
et, 1-year invasive coronary angiography (ICA) rates were low, ranging from 0.3% for those
ith little to no CAC to 8.9% for those with CAC 1,000. ICA occurred exclusively in
atients with a prior noninvasive procedure. In this study, CAC screening led to
ore frequent noninvasive testing in those with elevated scores, but was not used as a trigger
or ICA.ditorial Comment: Roger S. Blumenthal, Chao-Wei Hwang, Khurram Nasir, p. 1268OST-EFFECTIVENESS1271Cost Effectiveness of Enoxaparin for STEMI Treated With Fibrinolysiseo Marcoff, Zugui Zhang, Wei Zhang, Edward Ewen, Claudine Jurkovitz, Prisca Leguet, Paul Kolm,
illiam S. Weintraub
he ExTRACT–TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial
nfarction Treatment–Thrombolysis In Myocardial Infarction 25) trial demonstrated a
eduction in death or nonfatal myocardial infarction when enoxaparin was used instead of
nfractionated heparin (UFH) as adjunctive therapy for fibrinolysis in ST-segment elevation
yocardial infarction (STEMI) patients. This report by Marcoff and colleagues examined the
ost effectiveness of the 2 agents using patient-level clinical outcomes and resource use and
stimates of life expectancy gains. Index hospitalization costs were slightly lower by $126 in
he enoxaparin group, while 30-day costs were slightly higher by $102. Patients on
noxaparin gained an average of 0.12 life-years, with estimated total lifetime costs $1,207
igher, resulting in an incremental cost-effectiveness ratio of $5,700 per life-year gained.
hese results suggest that enoxaparin is a cost-effective strategy for STEMI patients.(continued on page A-24)
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GUALITY OF CARE1280Use of Warfarin for Patients AF and CHF Is Less Than Optimalonathan P. Piccini, Adrian F. Hernandez, Xin Zhao, Manesh R. Patel, William R. Lewis, Eric D. Peterson,
regg C. Fonarow, for the Get With The Guidelines Steering Committee and Hospitals
eart failure (HF) increases the risk of thromboembolic events in patients with atrial
brillation (AF). Piccini and colleagues analyzed over 72,000 HF admissions at 255 hospitals.
mong eligible HF patients without contraindications, the median prevalence of warfarin
herapy at discharge was 65% and did not improve during the 3.5 years of study. Major
actors associated with lower odds of warfarin use at discharge included increasing age,
onwhite race, anemia, and treatment in the South. Warfarin use also varied inversely with
HADS2 (congestive heart failure, hypertension, age 75, diabetes, and prior stroke or
ransient ischemic attack) score despite the increased risk of stroke with a higher CHADS2
core. Guideline-recommended warfarin use in patients with AF and HF is less than optimal
nd varies significantly.ditorial Comment: Javed Butler, Andreas Kalogeropoulos, p. 1290UTCOMES IN ACS1293Gastrointestinal Bleeding Significantly Increases Risks in ACS Patientsugenia Nikolsky, Gregg W. Stone, Ajay J. Kirtane, George D. Dangas, Alexandra J. Lansky,
rent McLaurin, A. Michael Lincoff, Frederick Feit, Jeffrey W. Moses, Martin Fahy, Steven V. Manoukian,
arvey D. White, E. Magnus Ohman, Michel E. Bertrand, David A. Cox, Roxana Mehran
ikolsky and colleagues assessed the incidence, predictors, and outcomes of gastrointestinal
leeding (GIB) in patients with acute coronary syndromes (ACS) enrolled in the ACUITY
Acute Catheterization and Urgent Intervention Triage Strategy) trial. GIB occurred in 1.3%
f trial subjects and was strongly associated with 30-day all-cause mortality (hazard ratio:
.87). Risk factors for GIB included older age, baseline anemia, longer duration of study drug
dministration before angiogram, smoking, ST-segment deviation, and diabetes. Almost 6%
f subjects who experienced a GIB also had stent thrombosis. These findings confirm that
IB has a strong negative impact on outcomes in ACS patients.(continued on page A-25)
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dORONARY ARTERY DISEASE
1303o Benefit for PCI in Older Adults With Stable Angina
The COURAGE Trial Subset Analysisoon K. Teo, Steven P. Sedlis, William E. Boden, Robert A. O’Rourke, David J. Maron,
amela M. Hartigan, Marcin Dada, Vipul Gupta, John A. Spertus, William J. Kostuk, Daniel S. Berman,
eslee J. Shaw, Bernard R. Chaitman, G. B. John Mancini, William S. Weintraub, on behalf of the
OURAGE Trial Investigators
lder patients with coronary artery disease (CAD) are at increased risk for cardiac events
ompared with younger patients, but it is unclear if percutaneous coronary intervention (PCI)
ould improve outcomes over optimal medical therapy (OMT). Teo and colleagues report on
pre-specified analysis of outcomes in stable CAD patients stratified by age in the
OURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG
valuation) trial. Patients 65 years of age had a 2- to 3-fold higher death rate, but had
imilar rates of myocardial infarction, stroke, and major cardiac events compared with younger
atients. The addition of PCI to OMT did not improve or worsen clinical outcomes in
atients 65 years of age. These data support the use of OMT as an initial management
trategy for stable CAD, regardless of age.EART RHYTHM DISORDERS
1309ctivating Autoantibodies Facilitate
AF in Patients With Graves’ Hyperthyroidismtavros Stavrakis, Xichun Yu, Eugene Patterson, Shijun Huang, Sean R. Hamlett, Laura Chalmers,
eji Pappy, Madeleine W. Cunningham, Syed A. Morshed, Terry F. Davies, Ralph Lazzara, David C. Kem
tavrakis and colleagues hypothesized that activating autoantibodies to 1-adrenergic
AA1AR) and activating autoantibodies to M2 muscarinic receptors (AAM2R) would
ncrease the likelihood of atrial fibrillation (AF) complicating Graves’ autoimmune
yperthyroidism. Immunoglobulin-G was purified from 38 patients with Graves’
yperthyroidism, approximately one-half of whom developed AF, and healthy controls. Both
f these autoantibodies were present in 82% of AF patients compared with only 10% of
raves’ patients who did not develop AF. Further studies confirmed that these autoantibodies
an decrease action potential duration and enhance early afterdepolarizations. AA1AR and
AM2R, when present in patients with Graves’ hyperthyroidism, facilitate
evelopment of AF.(continued on page A-26)
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bEFT VENTRICULAR DEFORMATION1317CRT Can Help to Normalize LV Twistatteo Bertini, Nina Ajmone Marsan, Victoria Delgado, Rutger J. van Bommel, Gaetano Nucifora,
. Jan Willem Borleffs, Giuseppe Boriani, Mauro Biffi, Eduard R. Holman, Ernst E. van der Wall,
artin J. Schalij, Jeroen J. Bax
his study explored the effects of cardiac resynchronization therapy (CRT) on left ventricular
LV) twist, which is emerging as a comprehensive index of LV function. LV twist is
easured using echocardiography and speckle tracking software as the difference (in degrees)
f apical and basal rotation. Subjects were studied before and after CRT. At baseline, peak
V twist in HF patients was 4.8° compared with 15° in controls. At 6-month follow-up,
eak LV twist significantly improved only in CRT responders, from 4.3° to 8.5°. CRT can
artially restore LV torsional mechanics by improving apical and basal rotation.EFT VENTRICULAR DEFORMATION1326Dynamic Obstruction Leads to Delayed Untwisting in HOCM Patientsianwen Wang, John M. Buergler, Kumuthavally Veerasamy, Yelena P. Ashton, Sherif F. Nagueh
ang and colleagues studied the etiology of reduced exercise capacity in patients with
ypertrophic obstructive cardiomyopathy (HOCM) by measuring left ventricular (LV) twist
efore and after septal reduction therapy. Untwisting was significantly delayed in hypertrophic
ardiomyopathy without obstruction and even longer in HOCM patients. The delayed
ntwisting was strongly correlated with LV end-diastolic pressure and peak oxygen
onsumption (VO2). After septal reduction, untwisting occurred earlier and accounted for the
ncrease in end-diastolic volume and peak VO2. These results provide a mechanistic link
etween dynamic obstruction and poor exercise tolerance in HOCM patients.
